Ypsomed Holding AG : Reinventing the business to stay on top of global trends
We initiate the coverage of Ypsomed with a target price of CHF 495 and an Outperform rating. As a leading developer and manufacturer of a broad portfolio of injection systems for the self-medication of liquid drugs, Ypsomed will benefit from major trends in the healthcare industry. The company is currently in a transformation process to exit non-core activities and to focus on the fast-growing and highly profitable Delivery Systems business. This is expected to lead on our estima...Ypsomed Holding operates in the field of medical technology and is an independent manufacturer of injection pens for pharmaceutical and biotech companies. Additionally, Co. supplies pen needles. Co.'s core business consists of developing and marketing products and services allowing patients to administer their own medication, in particular diabetes patients. Co. distributes its products worldwide by pharma and biotech companies under their own brand names. Co. operates production sites in Burgdorf, Solothurn, Grenchen and Tabor and has a sales and distribution network across Europe.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.